The brand new test searches for a protein known as EPCA-2 -- or early cancer of the prostate antigen 2. Unlike the PSA (prostate-specific antigen) protein which the present PSA test relies, this protein is not present in normal prostate cells. Rather, EPCA-2 happens in relatively considerable amounts only in cancer of the prostate cells.
The exam has been produced by Robert H. Getzenberg, PhD, director of urology research at Johns Hopkins University's Brady Urological Institute. Getzenberg started the job while still in the College of Pittsburgh the exam continues to be licensed towards the Dallas biotech firm Onconome Corporation.
Blood Test for Prostate Cancer
"We desired to find something which really recognized individuals with cancer of the prostate and never individuals with enlarged or infected prostates," Getzenberg informs WebMD. "This is because near to cancer specific once we may find. It was is extremely unique. It's 97% specific, and therefore should you test positive there's merely a 3% chance you do not have cancer of the prostate.Inch
Getzenberg includes a financial curiosity about the exam. But experts who don't are in position to gain in the test agree it has enormous potential.
Otis Brawley, MD, chief from the solid tumor service at Emory University's Winship Cancer Institute, calls the exam "important" and forecasts it will likely be broadly used.
Blood Test for Prostate Cancer
Charles A. Coltman Junior., MD, connect chairman for cancer control and prevention at San Antonio's Southwest Oncology Group, calls the findings "striking" and "amazing," although he alerts the test continues to be used on only a small amount of patients.
Ganesh Palapattu, MD, assistant professor of urology in the College of Rochester, concurs more studies should be done. But he informs WebMD the test is really a large step toward the "Ultimate Goal of cancer of the prostate recognition: less determining males with cancer of the prostate, but determining males with cancer of the prostate who've aggressive disease."
"This not just helps tell whether you've cancer of the prostate, but what type of cancer of the prostate you've,Inch Getzenberg states.
Getzenberg and co-workers report early studies from the EPCA-2 test within the April problem from the journal Urology.
EPCA-2 Test Beats PSA
Nobody is entirely pleased with the present PSA test for cancer of the prostate. A guy without cancer of the prostate might have high PSA levels. A guy with advanced cancer of the prostate might have really low PSA levels.
Getzenberg's team used the EPCA-2 test on bloodstream samples from the 3 different categories of people. Some maintained to possess early cancer of the prostate or late cancer of the prostate, plus some had other sorts of cancer. Some had enlarged prostates, although not cancer. Some were women, who've no prostate. Plus some were healthy males with normal PSA levels.
Blood Test for Prostate Cancer, prostate cancer, test, epca-2, blood test, psa test, cancer, psa, treatment, psa levels, prostate-specific antigen, doctor, risk, prostate cancer screening, ml, elevated psa levels, researchers, levels, psa level, screening, psa blood test, disease, diagnosis, prostate gland, prostate specific antigen, blood, symptoms, patients, the men,
Blood Test for Prostate Cancer
No comments:
Post a Comment